secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041417
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney reports Q2 2023 net loss of $34.8M; cash at $446.1M
-------------------------------------------------------------

- Net loss before noncontrolling interest $34.8M for Q2 2023 vs $22.1M in Q2 2022.
- R&D expenses $26.4M (up from $11.6M) driven by Phase 3 trial and manufacturing expansion.
- Cash, equivalents and marketable securities $446.1M as of June 30, 2023, down from $490.3M at Dec 31, 2022.
- Purchased 210,000 sq ft Greensboro facility; $458M investment planned by 2027 with $33.7M in tax incentives.
- Phase 3 proact 1 enrolling; interim data expected end 2024; proact 2 enrollment expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000095017023041417/0000950170-23-041417-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000095017023041417/prok-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041417

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer